Venture Funding Deals: Stem Cell Venture BlueRock Launches With Major Funding
Executive Summary
With backing from Bayer and others, the US-based venture will develop iPSC therapies for cardiovascular and neurodegenerative diseases; other notable new financings involve Cerevance, Goldfinch Bio, NeuroPharma and Tenaya. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced November through December 2016.
You may also be interested in...
Finance Watch: Rakuten Aspyrian Raises $150m VC Round For Laser-Activated Cancer Drugs
Private investors, including Japanese e-commerce mogul Hiroshi Mikitani, backed a $150m Series C round for Rakuten Aspyrian and its photoimmunotherapy platform. Also, pharma-backed therapeutic video game developer Akili boosts Series C to $68m, and Summit garners additional BARDA funding.
Deals In Depth: December 2022
The year's biggest M&A deal, along with billion dollar alliances marked out December's dealmaking credentials.
Deals In Depth: November 2022
Five $1bn+ alliances were penned in November. Topping the list was a potential $4.5bn deal between Arcturus Therapeutics and CSL Seqirus.